Physician profile
Andre D Sotelo
NPI 1982698577
$1,078.45
in general payments reported to CMS, 2019-2025
15 companies · $18.33 in 2025
The $18.33 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $14.99 · 2021: $184 · 2022: $462 · 2023: $114 · 2024: $285 · 2025: $18.33.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $418.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $417.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $247.18 | 2022-2024 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $172.73 | 2022-2024 | Andexxa |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $156.14 | 2022-2023 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $145.05 | 2020-2021 | |
| Amgen INC. | $115.92 | 2022 | |
| Mindray Ds USA, INC. | $47.49 | 2024 | Te7 Max, Te X |
| Abiomed | $39.68 | 2023-2024 | Impella |
| Abbvie INC. | $32.86 | 2022-2023 | Teflaro |
| Medtronic, INC. | $26.19 | 2021 | |
| Boston Scientific Corporation | $22.62 | 2022 | |
| Insmed, INC. | $18.33 | 2025 | Brinsupri, Arikayce |
| Pfizer INC. | $15.00 | 2021 | |
| Genzyme Corporation | $14.99 | 2022 | |
| Mallinckrodt Hospital Products INC. | $12.56 | 2021 | |
| United Therapeutics Corporation | $11.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andre Sotelo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.